New cocktail aims to wipe out prostate cancer before surgery

NCT ID NCT07516704

Not yet recruiting Disease control Sponsor: Zhongda Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether adding two drugs (darolutamide and homoharringtonine) to standard chemo and hormone therapy can more thoroughly clear high-risk prostate cancer before surgery. About 94 men will receive the combo for 7 weeks, then have their prostate removed to check for remaining cancer. The goal is to see if this approach leads to a complete or near-complete response in the tumor.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: docetaxel, darolutamide, homoharringtonine, and androgen deprivation therapy
What this could lead to: If successful, this could point toward a more effective pre-surgery treatment for high-risk prostate cancer, potentially improving long-term outcomes.
What could go wrong: This is a very early, small trial (94 people) with no control group, so results may not be conclusive. The drug combination also carries risks like infection, fatigue, and bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH RISK PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.